We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 153

Breveter le vivant : une question qui gène
  • Blake Cassels & Graydon LLP
  • Canada
  • October 27 2016

Si la Cour suprême du Canada (CSC) a déjà commenté l’épineuse question de savoir si les gènes peuvent être brevetés, aucun tribunal canadien n’a


VA Partners with IBM’s Watson for Genomics
  • Knobbe Martens
  • USA
  • July 8 2016

IBM's Watson for Genomics and the U.S. Department of Veterans Affairs (VA) just announced a public-private research partnership to study genomics and


Supreme Court Denies Sequenom’s Cert Petition, Leaving the Federal Circuit’s Interpretation of the MayoAlice Patent Eligibility Framework Intact For Now
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • June 27 2016

The Supreme Court today denied Sequenom Inc.’s petition for writ of certiorari, in which Sequenom asked the Court to review a decision of the Federal


IP developments in biotechnology and trade secrets
  • Ladas & Parry LLP
  • USA, European Union
  • June 6 2016

2016 has been a year of IP changes and these changes have had an effect upon biotechnology as well as trade secrets. Ariosa v. Sequenom was one of


Nature of nurture? Myriad decoded for non-biochemists
  • Shook Hardy & Bacon LLP
  • USA
  • July 31 2013

Gene patents became unstable with a clearly worded U.S. Supreme Court decision: "We merely hold that genes and the information they encode are not


The real impact for healthcare and biotechnology of the Supreme Court's decision in Myriad Genetics
  • Bradley Arant Boult Cummings LLP
  • USA
  • July 18 2013

On June 13, 2013, the Supreme Court issued a decision supposedly resolving the patentability of DNA in Association for Molecular Pathology v. Myriad


DNA and genetics patents: what impact will the Myriad decision have?
  • Dentons
  • USA
  • June 18 2013

Continuing a trend of narrowing the scope of patentable subject matter, the US Supreme Court's recentMyriad decision held that naturally occurring


Governing the code of life
  • Proskauer Rose LLP
  • USA
  • May 29 2012

What if the story of your life was written at birth - a “future diary” available for someone to read?


The United States Court of Appeals for the Federal Circuit rules that isolated DNA is patent eligible
  • Alston & Bird LLP
  • USA
  • August 17 2011

On July 29, 2011, the U.S. Court of Appeals for the Federal Circuit issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., a case that has been closely watched by the biotechnology community.


Federal Circuit upholds patentability of isolated DNA, but affirms invalidity of claims to methods “comparing” or “analyzing” genetic sequences
  • Locke Lord LLP
  • USA
  • August 2 2011

On July 29, 2011 a three-judge panel of the U.S. Court of Appeals for the Federal Circuit ruled that “isolated” human genes are patentable subject matter but that methods that merely compare or analyze genetic sequences are not patentable.